Cancer vaccine - BN ImmunoTherapeutics/National Cancer Institute

Drug Profile

Cancer vaccine - BN ImmunoTherapeutics/National Cancer Institute

Alternative Names: CEA-MUC-1/TRICOM; CV-301; CVAC-301; falimarev; inalimarev; PANVAC; PANVAC V/F; PANVAC-VF

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Therion Biologics
  • Developer BN ImmunoTherapeutics; Duke University; National Cancer Institute (USA)
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Carcinoembryonic antigen inhibitors; Immunostimulants; Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer
  • Phase I/II Non-small cell lung cancer
  • Discontinued Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 10 Mar 2017 Bavarian Nordic entered into a drug supply agreement with Roche for atezolizumab for planned CV 301 trial in bladder cancer
  • 10 Mar 2017 Bavarian Nordic plans a phase II trial for Bladder cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the end of 2017
  • 09 Nov 2016 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (SC) , (NCT02840994)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top